Oregon Shoulder Institute at Southern Oregon Orthopedics, Medford, Oregon, USA.
Midwest Orthopaedics at Rush, Rush University Medical Center, Chicago, Illinois, USA.
Am J Sports Med. 2022 Aug;50(10):2761-2766. doi: 10.1177/03635465221107939. Epub 2022 Jul 18.
The Latarjet procedure is one of the most well-established treatment options for anterior shoulder instability. However, meaningful clinical outcomes after this surgery have not been defined.
This study aimed to establish the minimal clinically important difference (MCID) and Patient Acceptable Symptom State (PASS) for commonly used outcome measures in patients undergoing the Latarjet procedure and determine correlations between preoperative patient characteristics and achievement of MCID or PASS.
Case series; Level of evidence, 4.
A multicenter retrospective review at 4 institutions was performed to identify patients undergoing primary open Latarjet procedure with minimum 2-year follow-up. Data collected included patient characteristics (age, sex, sports participation), radiological parameters (glenoid bone loss, off-track Hill-Sachs lesion), and 4 patient-reported outcome measures (collected preoperatively and 2 years postoperatively): the American Shoulder and Elbow Surgeons (ASES) score, the Single Assessment Numeric Evaluation (SANE), the visual analog scale (VAS) for pain, and the Western Ontario Shoulder Instability Index (WOSI). The MCID and PASS for each outcome measure were calculated, and Pearson and Spearman coefficient analyses were used to identify correlations between MCID or PASS and preoperative variables (age, sex, sports participation, glenoid bone loss, off-track Hill-Sachs lesion).
A total of 156 patients were included in the study. The MCID values for ASES, SANE, VAS pain, and WOSI were calculated to be 9.6, 12.4, 1.7, and 254.9, respectively. The PASS values for ASES, SANE, VAS pain, and WOSI were 86.0, 82.5, 2.5, and 571.0, respectively. The rates of patients achieving MCID were 61.1% for VAS pain, 71.6% for ASES, 74.1% for SANE, and 84.2% for WOSI. The rates of achieving PASS ranged from 78.4% for WOSI to 84.0% for VAS pain. There was no correlation between any of the studied preoperative variables and the likelihood of achieving MCID or PASS.
This study defined MCID and PASS values for 4 commonly used outcome measures in patients undergoing the Latarjet procedure. These findings are essential for incorporating patient perspectives into the clinical effectiveness of the Latarjet procedure and provide valuable parameters for the design and interpretation of future clinical trials.
Latarjet 手术是治疗肩关节前不稳定的最成熟的治疗方法之一。然而,这种手术后的有意义的临床结果尚未确定。
本研究旨在确定 Latarjet 手术后常用结局测量指标的最小临床重要差异(MCID)和患者可接受的症状状态(PASS),并确定术前患者特征与 MCID 或 PASS 之间的相关性。
多中心回顾性研究;证据水平,4 级。
在 4 家机构进行了多中心回顾性研究,以确定接受初次开放 Latarjet 手术且随访时间至少 2 年的患者。收集的数据包括患者特征(年龄、性别、运动参与情况)、影像学参数(肩盂骨丢失、肩盂外移 Hill-Sachs 损伤)和 4 项患者报告的结局测量指标(术前和术后 2 年采集):美国肩肘外科医师协会(ASES)评分、单项评估数值评估(SANE)、疼痛视觉模拟量表(VAS)和西部Ontario 肩不稳定指数(WOSI)。计算每个结局测量指标的 MCID 和 PASS,并使用 Pearson 和 Spearman 系数分析来确定 MCID 或 PASS 与术前变量(年龄、性别、运动参与情况、肩盂骨丢失、肩盂外移 Hill-Sachs 损伤)之间的相关性。
共纳入 156 例患者。计算得出 ASES、SANE、VAS 疼痛和 WOSI 的 MCID 值分别为 9.6、12.4、1.7 和 254.9。ASES、SANE、VAS 疼痛和 WOSI 的 PASS 值分别为 86.0、82.5、2.5 和 571.0。VAS 疼痛、ASES、SANE 和 WOSI 的患者达到 MCID 的比例分别为 61.1%、71.6%、74.1%和 84.2%。达到 PASS 的比例范围为 WOSI 的 78.4%至 VAS 疼痛的 84.0%。术前任何研究变量与 MCID 或 PASS 的可能性均无相关性。
本研究确定了 Latarjet 手术后常用结局测量指标的 MCID 和 PASS 值。这些发现对于将患者视角纳入 Latarjet 手术的临床效果至关重要,并为未来临床试验的设计和解释提供了有价值的参数。